Israel
OCON Therapeutics is spearheading advancements in women's healthcare with its innovative, non-invasive intra-uterine drug delivery solutions. Founded in 2020, the company operates out of Israel and focuses on enhancing the quality of life and reproductive autonomy for women worldwide.
Central to its achievement is the proprietary IUB™ platform, which employs a novel ball-shaped technology made from super-elastic alloy Nitinol. This platform underpins the IUB™ Ballerine®, a CE-approved, hormone-free copper intrauterine contraceptive, already trusted by over 100,000 women across 24 countries. With an effective duration of up to 5 years, it reflects OCON's commitment to safe, long-term health solutions.
OCON is expanding its impact through the IUB™ SEAD, a breakthrough device currently in phase II clinical trials addressing abnormal uterine bleeding (AUB). The SEAD offers a pain-free, cost-efficient alternative to traditional procedures. Supported by a robust patent portfolio, OCON is poised for growth, bolstered by a recent $10.00M Series A led by RH Capital and others.
